Published in Telemedicine Business Week, May 9th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Clarient.
Report 1: Clarient, Inc. (Nasdaq: CLRT), a technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the Company's existing HER-2 testing practices meet or exceed new HER-2 testing guidelines recently formulated by the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) and published in the January issues of the Journal of Clinical Oncology and the Archives of Pathology and Laboratory and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Telemedicine Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.